#None #Abbott #cancer screening #Cologuard Plus

Abbott's Cologuard Plus Receives CE Mark for Colorectal Cancer Screening in Europe

In a significant advancement for colorectal cancer screening, Abbott Laboratories has announced that its Cologuard Plus has received the CE marking under the European Union's In Vitro Diagnostic Regulation (IVDR). This recognition allows Abbott to launch this innovative non-invasive test in European markets, providing a vital tool in the battle against colorectal cancer.

What is Cologuard Plus?

Cologuard Plus is an advanced screening test that analyzes DNA in stool samples, specifically targeting the detection of colorectal cancer and advanced precancerous lesions. One of its standout features is that it requires no bowel preparation, dietary restrictions, or sedation, making it both convenient and user-friendly for patients.

This new test represents a major improvement over its predecessor, the original Cologuard, which had already made a notable impact on colorectal cancer screening in the United States. The CE marking ensures that Cologuard Plus is compliant with stringent European medical device regulations, thereby maintaining the highest safety and efficacy standards.

Clinical Effectiveness

The pivotal BLUE-C study, a large-scale trial evaluating the effectiveness of Cologuard Plus, showcased impressive results. With over 20,000 participants, the test demonstrated:

• - 95% sensitivity for detecting colorectal cancer
• - 94% specificity, minimizing false positive results
• - 43% sensitivity for advanced precancerous lesions
• - A 74% sensitivity for high-grade dysplasia, known to escalate into cancer
• - A significant reduction of up to 40% in false positive results compared to the original Cologuard test

These findings were published in the New England Journal of Medicine, supporting the clinical capability of Cologuard Plus in the early detection of colorectal cancer.

Addressing the Colorectal Cancer Burden in Europe

Colorectal cancer is one of the most prevalent cancers in Europe, with an estimated 538,000 new cases diagnosed in 2022 alone. Alarmingly, it accounts for over 13% of all cancer diagnoses within the European Union. Early detection through effective screening is crucial, as it can significantly increase treatment efficacy and detect precancerous lesions before they develop into full-blown cancer.

However, participation rates for colorectal cancer screening show considerable variation across European countries. In 2022, only 42% of the target population in EU member states participated in screening practices, highlighting a pressing need for enhanced access and awareness of screening options.

Dr. Cesare Hassan, a prominent gastroenterology professor at the Humanitas University in Milan, emphasized the importance of expanding access to effective, non-invasive screening tools like Cologuard Plus. By increasing accessibility, it is believed that more colorectal cancers can be identified at earlier stages.

The User-Friendly Experience

Patients utilizing Cologuard Plus will collect stool samples in the comfort of their homes, eliminating the need for hospital visits or invasive procedures. The test focuses on discovering DNA markers related to colorectal abnormalities and traces of blood in the sample, thus providing comprehensive insights into an individual's colorectal health without significant disruption to their daily lives.

Future Steps

As Abbott prepares for the launch of Cologuard Plus in selected European markets, timelines and availability will vary based on local healthcare systems and reimbursement processes. The company's commitment, as noted by Jake Orville, Abbott's senior vice president of cancer diagnostics, is to empower individuals through efficient and accessible screening solutions to save lives.

Conclusion

Abbott's Cologuard Plus represents a critical step forward in the fight against colorectal cancer. By obtaining CE marking, Abbott is poised to significantly impact public health in Europe, improving access to vital cancer screening options for potentially millions of adults aged 45 and over. As they roll out this innovative test, the ultimate goal remains to reduce the incidence and mortality rates associated with colorectal cancer throughout the continent.

For more information about Abbott and its healthcare innovations, visit www.abbott.com.